Personalized Neoantigen Vaccines through Expanded Access

Traditional vaccines revolutionized the treatment of disease. In recent years, personalized vaccines have shown promise in combating cancer. In addition, technological advances in genetic sequencing, algorithms to identify neoantigens, and peptide manufacturing have vastly improved the personalized vaccine development process.

Of critical importance, the FDA introduced the “Expanded Access” rule which, as you know, gives an individual the right to try a medical treatment outside of clinical trials when no comparable alternative options are available.

Turn to JLF

The Jaime Leandro Foundation (JLF) is a private nonprofit organization established to deliver breakthrough cancer treatments based on the latest innovations in research and personalized medicine and leveraging the Expanded Access rule — also known as “Compassionate Use.” We bring the critical components together, partnering with expert academic and commercial institutions to develop and deliver therapeutic vaccines personalized for each patient. Learn more.

Partners

Our partners are at the forefront of medicine and science. Each is an industry leader providing cutting-edge expertise and technology. JLF consults with the patient, coordinates with partners, and helps both navigate the entire process.